The genetics of interdigitating dendritic cell sarcoma share some changes with Langerhans cell histiocytosis in select cases

O’Malley, Dennis P.; Zuckerberg, Lawrence; Smith, Lauren B.; Barry, Todd; Gunn, Shelly; Orazi, Attilio; Kim, Young S.; Weiss, Lawrence M.

doi:10.1016/j.anndiagpath.2013.10.003

Cited by 15 publications

(6 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These tumors, although rare, are not specifically thought to be related to the same lineage as Langerhans cells [6]. However, recent studies have shown significant plasticity in the cell lineage and differentiation of histiocytic and dendritic cells [15]. In our experience, we have seen cases of LCH with differentiation toward interdigitating dendritic cells.…”

Section: Discussionmentioning

confidence: 88%

Evidence of BRAF V600E in indeterminate cell tumor and interdigitating dendritic cell sarcoma

O’Malley

Agrawal²,

Grimm³

et al. 2015

Annals of Diagnostic Pathology

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 88%

Evidence of BRAF V600E in indeterminate cell tumor and interdigitating dendritic cell sarcoma

O’Malley

Agrawal²,

Grimm³

et al. 2015

Annals of Diagnostic Pathology

Self Cite

View full text Add to dashboard Cite

“…Given the rarity of histiocytic sarcoma and Langerhans cell sarcoma in people and their shared clinical features, they will be considered together in this review as histiocytic neoplasia (HS) [ 35 ]. Treatment for DS and HS are broadly similar, with the majority of patients undergoing surgical resection followed by adjuvant chemotherapy [ 33 , 35 , 36 ], despite which up to 30% of DS patients will demonstrate metastasis [ 33 ] and the majority of patients with HS will succumb to the disease within two years [ 34 , 37 ]. There is a clear need for more targeted therapeutics and the establishment of standardized treatment protocols in HS/DS; however the rarity of these tumors is reflected in the small volume of literature describing their biological and clinical characteristics [ 36 , 37 ].…”

Section: The Comparative Value Of Canine Hm To Human Medicinementioning

confidence: 99%

Canine Histiocytic Malignancies—Challenges and Opportunities

Kennedy

Thomas

Breen

2016

Veterinary Sciences

View full text Add to dashboard Cite

Canine histiocytic malignancies (HM) are aggressive tumors that occur with particularly high frequency in certain breeds including Bernese mountain dogs and flat-coated retrievers. Robust diagnosis of HM commonly utilizes immunohistochemical stains that are broadly ineffective on formalin-fixed tissues; thus the diagnosis is often one of exclusion. Clinical outcomes are generally poor, with frequent metastasis and therapeutic failure lowering overall survival at time of diagnosis to an average of less than two months in the majority of published work. The limited understanding of the molecular mechanisms underlying HM has hindered the development of more effective diagnostic modalities and the identification of therapeutic targets. A potential avenue exists for advancing clinical management of canine cancers through extrapolation from a close counterpart in human medicine. Historically, HM have been compared to the rare and understudied subset of human cancers involving the dendritic lineage, such as dendritic cell sarcoma or Langerhans cell sarcoma. Recent data have now thrown into question the cellular origin of HM, suggesting that the disease may originate from the macrophage lineage. This review summarizes existing knowledge of HM from the clinical, histologic and molecular perspectives, and highlights avenues for future research that may aid the development of novel diagnostic and therapeutic approaches. In turn, a more advanced appreciation of the mechanisms underlying HM should clarify their cellular origin and identify appropriate opportunities for synergistic extrapolation between related canine and human cancers.

show abstract

“…Contrasting with LCH, which generally has a normal karyotype and ,5 somatic mutations, 37 MH usually has frequent chromosomal gains or losses. 62 …”

Section: Primary Malignant Histiocytosesmentioning

confidence: 99%

Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages

Emile

Abla

Fraïtag

et al. 2016

Blood

Self Cite

1,165

1,251

View full text Add to dashboard Cite

The histiocytoses are rare disorders characterized by the accumulation of macrophage, dendritic cell, or monocyte-derived cells in various tissues and organs of children and adults. More than 100 different subtypes have been described, with a wide range of clinical manifestations, presentations, and histologies. Since the first classification in 1987, a number of new findings regarding the cellular origins, molecular pathology, and clinical features of histiocytic disorders have been identified. We propose herein a revision of the classification of histiocytoses based on histology, phenotype, molecular alterations, and clinical and imaging characteristics. This revised classification system consists of 5 groups of diseases: (1) Langerhans-related, (2) cutaneous and mucocutaneous, and (3) malignant histiocytoses as well as (4) Rosai-Dorfman disease and (5) hemophagocytic lymphohistiocytosis and macrophage activation syndrome. Herein, we provide guidelines and recommendations for diagnoses of these disorders.

show abstract

The genetics of interdigitating dendritic cell sarcoma share some changes with Langerhans cell histiocytosis in select cases

Cited by 15 publications

References 29 publications

Evidence of BRAF V600E in indeterminate cell tumor and interdigitating dendritic cell sarcoma

Evidence of BRAF V600E in indeterminate cell tumor and interdigitating dendritic cell sarcoma

Canine Histiocytic Malignancies—Challenges and Opportunities

Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages

Contact Info

Product

Resources

About